decoy20
decoy20: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Indaptus Therapeutics, Inc. (INDP) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Frequently asked questions
Who is developing decoy20?
decoy20 is being developed by Indaptus Therapeutics, Inc..
How many clinical trials involve decoy20?
BioSniper tracks 1 clinical trial involving decoy20.
Get deeper analysis on decoy20
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis